Diurnal Group PLC Director Dealings and Issue of Equity (3368K)
21 April 2020 - 7:05PM
UK Regulatory
TIDMDNL
RNS Number : 3368K
Diurnal Group PLC
21 April 2020
21 April 2020
Diurnal Group plc
("Diurnal" or the "Company")
Director Dealings and Issue of Equity
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical
company targeting patient needs in chronic endocrine (hormonal)
diseases, announces the following share dealings by Directors:
John Goddard, Non-Executive Director, was today issued and
allotted 12,963 new Ordinary Shares at an effective price of nil
pence per Ordinary Share as part of a pre-existing arrangement
whereby he receives shares in the Company in lieu of part of his
Non-executive director fees, issued from the Company's Employee
Benefit Trust. Following the transaction, John Goddard has a total
interest of 188,589 Ordinary Shares, representing 0.2% of the
enlarged total voting rights in the Company.
Application will be made for admission of the 12,963 new
Ordinary Shares, which is anticipated to occur at 8:00am on Monday
27 April 2020 ("Admission"). The New Ordinary Shares rank pari
passu with the existing shares of the Company. Following issue of
the New Ordinary Shares, the Company's issued ordinary share
capital consists of 121,633,387 ordinary shares. The Company does
not hold any shares in treasury. Therefore, the total number of
ordinary shares with voting rights is 121,633,387.
The above figure of 121,633,387 may be used by shareholders as
the denominator for the calculations by which they will determine
if they are required to notify their interest in, or a change to
their interest in the Company under the FCA's Disclosure Guidance
and Transparency Rules.
Details of the full notifications received by the Company are
set out below:
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name John Goddard
------------------------------------- -----------------------------------------
2 Reason for the notification
--------------------------------------------------------------------------------
a) Position/status Non-executive Director
------------------------------------- -----------------------------------------
b) Initial notification Initial notification
/Amendment
------------------------------------- -----------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--------------------------------------------------------------------------------
a) Name Diurnal Group plc
------------------------------------- -----------------------------------------
b) LEI 213800I2HNUNZN1LDH29
------------------------------------- -----------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
--------------------------------------------------------------------------------
a) Description of the Ordinary shares of 5 pence each in
financial instrument, Diurnal Group plc
type of instrument
Identification code GB00BDB6Q760
b) Nature of the transaction Acquisition of ordinary shares
------------------------------------- -----------------------------------------
c) Price(s) and volume(s)
------------------- -----------------
Price(s) Volume(s)
------------------- -----------------
Nil 12,963
-------------------------------------------------------------- -----------------
d) Aggregated information
- Aggregated volume As above
- Price
e) Date of the transaction 21 April 2020
------------------------------------- -----------------------------------------
f) Place of the transaction XLON
------------------------------------- -----------------------------------------
For further information, please visit www.diurnal.co.uk or
contact:
+44 (0)20 3727
Diurnal Group plc 1000
Martin Whitaker, Chief Executive Officer
Richard Bungay, Chief Financial Officer
Panmure Gordon (UK) Limited (Nominated Adviser +44 (0) 20 7886
and Joint Broker) 2500
Corporate Finance: Freddy Crossley, Emma Earl
Corporate Broking: James Stearns
+44 (0)20 7894
Cantor Fitzgerald Europe (Joint Broker) 7000
Corporate Finance: Phil Davies, Will Goode,
Michael Boot
Healthcare Equity Sales: Andrew Keith
+44 (0)20 3727
FTI Consulting (Media and Investor Relations) 1000
Simon Conway
Victoria Foster Mitchell
Notes to Editors
About Diurnal Group plc
Founded in 2004, Diurnal is a UK-headquartered, European-based
specialty pharma company developing pharmaceutical products for the
global market for the life-long treatment of chronic endocrine
conditions, including Congenital Adrenal Hyperplasia and Adrenal
Insufficiency. Its expertise and innovative research activities
focus on circadian-based endocrinology to yield novel product
candidates in the rare and chronic endocrine disease arena.
For further information about Diurnal, please visit
www.diurnal.co.uk
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHFIFIASLILFII
(END) Dow Jones Newswires
April 21, 2020 05:05 ET (09:05 GMT)
Diurnal (LSE:DNL)
Historical Stock Chart
From Apr 2024 to May 2024
Diurnal (LSE:DNL)
Historical Stock Chart
From May 2023 to May 2024